AVI BioPharma (AVII) Partner Receives European Approval for a New Cobalt Chromium Bare Metal Stent
More News related to AVII
- AVI BioPharma Announces Approval to Conduct Systemic Trial for Duchenne Muscular Dystrophy and Second Quarter 2008 Financial Results
- AVI BioPharma Announces Second Quarter 2008 Financial Results Conference Call
- AVI BioPharma to Present at BMO Healthcare Conference
- AVI BioPharma Appoints New Senior Vice President and Chief Financial Officer
- AVI BioPharma (AVII) Partner Receives European Approval for a New Cobalt Chromium Bare Metal Stent
More News related to FDA
- Mylan (MYL) Subsidiary, Alphapharm, Wins Patent Challenge on First-to-fFile Opportunity Razadyne(R) Tablets
- Amylin (AMLN) Gets A Friend After Yesterday's 25% Sell-Off
- Barr Labs (BRL) Receives Final FDA Approval for Generic Version of Razadyne(R) Tablets
- Pro-Pharmaceuticals (PRW) Receives FDA IND Application for Use of DAVANAT(R)
- Valeant Pharmaceuticals (VRX) and GlaxoSmithKline Enter Collaboration for Retigabine
AVI BioPharma, Inc. (NASDAQ: AVII) announced that its partner in its cardiovascular program, Global Therapeutics, the cardiology unit of Cook Medical, has received CE Mark approval for a new cobalt chromium bare metal stent. The device, the Global Therapeutics GTX Coronary Stent System, is also the platform for a breakthrough drug-eluting stent (DES) technology which utilizes AVI-5126, developed by AVI. The drug candidate is an improved version of antisense gene therapy to inhibit the proliferation of c-myc, a gene known to be involved in the intimal hyperplasia which underlies the process of vessel restenosis. Cook Medical management indicates that the clinical trial is expected to begin in the third quarter of 2008 in Europe.
AVI BioPharma, Inc. (AVI) is a biopharmaceutical company developing therapeutic products principally based on third-generation NeuGene antisense technology. [SM]
Related Categories
FDAStocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
